Open AccessImmunoexpression of ttf1 and p63 differentiates lung adenocarcinomas in sputum samples
Author(s) -
VS Veena,
VN Saritha,
Preethi Sara George,
K Rajan,
K Jayasree,
K. Sujathan
Publication year - 2021
Publication title -
journal of cytology/journal of cytology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.267
H-Index - 19
eISSN - 0974-5165
pISSN - 0970-9371
DOI - 10.4103/joc.joc_252_16
Subject(s) - medicine , lung cancer , sputum , adenocarcinoma , pathology , lung , differential diagnosis , epidermal growth factor receptor , subtyping , kras , immunohistochemistry , oncology , cancer , tuberculosis , colorectal cancer , computer science , programming language
Differentiating NSCLC as either adeno or squamous type and identification of Epidermal Growth Factor Receptor (EGFR) mutations is clinically relevant for lung cancer patients for selecting treatment. Thyroid transcription factor-1 (TTF-1) and p63 were demonstrated as useful markers for histologic typing of lung cancer. Mutation and overexpression of EGFR has been reported in a subset of non-small cell lung cancers. If these markers can be validated for the differential diagnosis of adenocarcinoma in a sputum sample itself, it will be highly beneficial for lung cancer patients.